Long Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Long Li has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Yuxiao Lai
Centre for Translational Medicine Research and Development, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
3 shared publications - Wei Zhang
Centre for Translational Medicine Research & Development, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
2 shared publications - Yangyi Nie
Centre for Translational Medicine Research and Development, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
2 shared publications - Yuanchi Zhang
Centre for Translational Medicine Research and Development, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
2 shared publications - Yuyang Zhang
National Innovation Center for Advanced Medical Devices, Shenzhen 518131, China
2 shared publications - Along Guo
Centre for Translational Medicine Research & Development, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
1 shared publication
Latest Publications
- Open Access
Design and Fabrication of Low-Temperature 3D-Printed Bioactive Polyurethane/MnO2 Scaffolds for Bone Repair
Bone defect repair presents a significant clinical challenge, especially for critical-sized defects, due to the limitation of conventional 3D-printed scaffolds to provide simultaneous mechanical support and bioactivity. Herein, this study developed a bioactive composite scaffold through a low-temperature rapid prototyping (LT-RP) 3D printing technology. The scaffold comprises a polyurethane (PU) matrix enhanced with bioactive manganese dioxide (MnO2) nanoparticles, combining structural integrity with versatile bioactivity for bone repair. By incorporating 2, 6-pyridinedimethanol (PDM) into the PU molecular network, a coordination system is formed, enabling homogeneous distribution and structural integration of MnO2 nanoparticles. As designed, the bioactive scaffolds are fabricated through LT-RP 3D printing technology with a regular porous architecture for improving cell growth. With 10 wt% MnO2, the scaffolds (PPM10) have optimal comprehensive properties, with a modulus of ~14.1 MPa, improved thermal stability, good cytocompatibility, and enhanced osteogenic differentiation. Furthermore, in vitro degradation tests revealed the responsive release of Mn2+ from the PPM10 scaffolds in a glutathione-rich microenvironment. This functionality indicates the potential of the scaffolds to modify the tumor microenvironment for ultimate bone regeneration after bone tumor surgery.
Open AccessDesign and Fabrication of Low-Temperature 3D-Printed Bioactive Polyurethane/MnO2 Scaffolds for Bone Repair
Bone defect repair presents a significant clinical challenge, especially for critical-sized defects, due to the limitation of conventional 3D-printed scaffolds to provide simultaneous mechanical support and bioactivity. Herein, this study developed a bioactive composite scaffold through a low-temperature rapid prototyping (LT-RP) 3D printing technology. The scaffold comprises a polyurethane (PU) matrix enhanced with bioactive manganese dioxide (MnO2) nanoparticles, combining structural integrity with versatile bioactivity for bone repair. By incorporating 2, 6-pyridinedimethanol (PDM) into the PU molecular network, a coordination system is formed, enabling homogeneous distribution and structural integration of MnO2 nanoparticles. As designed, the bioactive scaffolds are fabricated through LT-RP 3D printing technology with a regular porous architecture for improving cell growth. With 10 wt% MnO2, the scaffolds (PPM10) have optimal comprehensive properties, with a modulus of ~14.1 MPa, improved thermal stability, good cytocompatibility, and enhanced osteogenic differentiation. Furthermore, in vitro degradation tests revealed the responsive release of Mn2+ from the PPM10 scaffolds in a glutathione-rich microenvironment. This functionality indicates the potential of the scaffolds to modify the tumor microenvironment for ultimate bone regeneration after bone tumor surgery.
- Open Access
Exosomes Derived from Mg-Preconditioned Bone Mesenchymal Stem Cells Promote Angiogenesis and Osteogenesis for Osteonecrosis Treatment
Steroid-induced osteonecrosis of the femoral head (SONFH) is a common and refractory orthopedic disorder, often resulting from prolonged or high-dose glucocorticoid use that impairs bone repair and vascularization. The critical impact of exosomes derived from bone mesenchymal stem cells (BMSCs) in bone regeneration has drawn increasing attention. In this study, we developed a novel type of exosomes derived from Magnesium-preconditioned BMSCs (Mg-Exos) and evaluated their therapeutic potential. In vitro experiments demonstrated that Mg-Exos effectively counteracted Dex-induced impairment in the angiogenic function of human umbilical vein endothelial cells (HUVECs) and the osteogenic differentiation of BMSCs. These findings highlight the promise of Mg-Exos as a potential cell-free therapeutic strategy for SONFH, acting through the concurrent enhancement of vascularization and bone formation. Consequently, this work lays a solid foundation for the future application of Mg-Exos in treating SONFH.
Open AccessExosomes Derived from Mg-Preconditioned Bone Mesenchymal Stem Cells Promote Angiogenesis and Osteogenesis for Osteonecrosis Treatment
Steroid-induced osteonecrosis of the femoral head (SONFH) is a common and refractory orthopedic disorder, often resulting from prolonged or high-dose glucocorticoid use that impairs bone repair and vascularization. The critical impact of exosomes derived from bone mesenchymal stem cells (BMSCs) in bone regeneration has drawn increasing attention. In this study, we developed a novel type of exosomes derived from Magnesium-preconditioned BMSCs (Mg-Exos) and evaluated their therapeutic potential. In vitro experiments demonstrated that Mg-Exos effectively counteracted Dex-induced impairment in the angiogenic function of human umbilical vein endothelial cells (HUVECs) and the osteogenic differentiation of BMSCs. These findings highlight the promise of Mg-Exos as a potential cell-free therapeutic strategy for SONFH, acting through the concurrent enhancement of vascularization and bone formation. Consequently, this work lays a solid foundation for the future application of Mg-Exos in treating SONFH.
- Open Access
- 27 December 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 88
LL-37-Coupled Porous Composite Scaffold for the Treatment of Infected Segmental Bone Defect
Increased multiantibiotic-resistant bacteria means that infected bone defects remain a significant challenge to clinics. Great interest has emerged in the use of non-antibiotic antimicrobials to reduce the rate of multiantibiotic-resistant bacterial infection and facilitate bone regeneration. The cationic antimicrobial peptide LL-37 is the sole human cathelicidin and has shown nonspecific activity against a broad spectrum of microorganisms. In this study, we fabricated the poly(lactic-co-glycolic acid)/β-calcium phosphate/peptide LL-37 (PLGA/TCP/LL-37, PTL) scaffold with low-temperature 3D-printing technology for the treatment of infected segmental bone defects. The prepared scaffolds were divided into three groups: a high LL-37 concentration group (PTHL), low LL-37 concentration group (PTLL) and blank control group (PT). The cytocompatibility and antimicrobial activity of the engineered scaffolds were tested in vitro, and their osteogenesis properties were assessed in vivo in a rat infected bone defect model. We found the fabricated PTL scaffold had a well-designed porous structure that could support a steady and prolonged LL-37 release. Furthermore, the PTHL group showed strong antibacterial activity against Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) without any inhibition of the proliferation or alkaline phosphatase activity of rat bone marrow mesenchymal stem cells (BMSCs) in vitro. In addition, the infected femoral defects implanted with PTHL group displayed new bone formation in four weeks without any evidence of residual bacteria, which showed similar antibacterial outcomes to the vancomycin and cancellous bone mixture group. In conclusion, the PTHL composite scaffold is a promising non-antibiotic antimicrobial graft with good biodegradability, biocompatibility, and osteogenic capability for infected bone defects.
- 27 December 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 88
Open AccessLL-37-Coupled Porous Composite Scaffold for the Treatment of Infected Segmental Bone Defect
Increased multiantibiotic-resistant bacteria means that infected bone defects remain a significant challenge to clinics. Great interest has emerged in the use of non-antibiotic antimicrobials to reduce the rate of multiantibiotic-resistant bacterial infection and facilitate bone regeneration. The cationic antimicrobial peptide LL-37 is the sole human cathelicidin and has shown nonspecific activity against a broad spectrum of microorganisms. In this study, we fabricated the poly(lactic-co-glycolic acid)/β-calcium phosphate/peptide LL-37 (PLGA/TCP/LL-37, PTL) scaffold with low-temperature 3D-printing technology for the treatment of infected segmental bone defects. The prepared scaffolds were divided into three groups: a high LL-37 concentration group (PTHL), low LL-37 concentration group (PTLL) and blank control group (PT). The cytocompatibility and antimicrobial activity of the engineered scaffolds were tested in vitro, and their osteogenesis properties were assessed in vivo in a rat infected bone defect model. We found the fabricated PTL scaffold had a well-designed porous structure that could support a steady and prolonged LL-37 release. Furthermore, the PTHL group showed strong antibacterial activity against Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) without any inhibition of the proliferation or alkaline phosphatase activity of rat bone marrow mesenchymal stem cells (BMSCs) in vitro. In addition, the infected femoral defects implanted with PTHL group displayed new bone formation in four weeks without any evidence of residual bacteria, which showed similar antibacterial outcomes to the vancomycin and cancellous bone mixture group. In conclusion, the PTHL composite scaffold is a promising non-antibiotic antimicrobial graft with good biodegradability, biocompatibility, and osteogenic capability for infected bone defects.